US2009269337A1PendingUtilityA1

Compositions and methods for treating diabetes

55
Assignee: WARATAH PHARMACEUTICALS INCPriority: Jun 7, 2002Filed: Apr 8, 2009Published: Oct 29, 2009
Est. expiryJun 7, 2022(expired)· nominal 20-yr term from priority
Inventors:Stephen BrandAntonio Cruz
A61P 43/00A61K 31/522A61K 38/21A61K 31/535A61P 3/10A61K 38/28A61K 31/573A61K 38/1808A61K 45/06A61K 31/525A61K 38/2207A61K 31/436A61K 31/663A61P 37/06A61K 31/5377A61K 38/19A61K 38/16
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods for islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided.

Claims

exact text as granted — not AI-modified
1 .- 77 . (canceled) 
   
   
       78 . A pharmaceutical composition comprising an agent for suppressing an immune response and a gastrin/CCK receptor ligand in the absence of a EGF receptor ligand, wherein the agent for suppressing immune response is at least one selected from the group consisting of: hul 124; BTI-322; allotrap-HLA-B270; OKT4A; Enlimomab; ABX-CBL; OKT3; ATGAM; basiliximab; daclizumab; antithymocyte immunoglobulin; ISAtx247; Medi-500; Medi-507; Alefacept; efalizumab; infliximab; and an interferon and the gastrin/CCK receptor ligand is gastrin 17(Leu 15). 
   
   
       79 . A method of treating a diabetic subject comprising administering to said subject an agent that increases islet neogenesis and an agent that suppresses an immune response in the absence of a EGF receptor ligand, wherein said agent that increases islet neogenesis is gastrin 17(Leu 15) and wherein the agent for suppressing immune response is at least one selected from the group consisting of: hul 124; BTI-322; allotrap-HLA-B270; OKT4A; Enlimomab; ABX-CBL; OKT3; ATGAM; basiliximab; daclizumab; antithymocyte immunoglobulin; ISAtx247; Medi-500; Medi-507; Alefacept; efalizumab; infliximab; and an interferon and the gastrin/CCK receptor ligand is gastrin 17(Leu 15). 
   
   
       80 . The method according to  claim 79 , wherein said agent that increases islet neogenesis and said agent that suppresses an immune response are administered sequentially. 
   
   
       81 . The method according to  claim 80 , wherein the subject is a human. 
   
   
       82 . The method according to  claim 80 , wherein the diabetic subject has recent onset diabetes.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.